19064-65-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Methoxypyridazine is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Flavoring Agent Applications:
In the food industry, 3-Methoxypyridazine is used as a flavoring agent to provide a nutty, roasted, or coffee-like aroma, enhancing the sensory experience of food products.
Used in Chemical Research:
3-Methoxypyridazine is utilized in chemical research for the study of heterocyclic compounds and their potential applications in various fields.
Safety Precautions:
It is important to handle 3-Methoxypyridazine with care, as it can be harmful if it comes into contact with the skin, or if it is ingested or inhaled. Proper safety measures should be taken during its use and storage to minimize potential risks.

InChI:InChI=1/C5H6N2O/c1-8-5-3-2-4-6-7-5/h2-4H,1H3

Upstream product

• 1120-95-2 3-chloropyridazine 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 141-30-0 3,6-dichlorpyridazine 
• 1722-10-7 3-chloro-6-methoxypyridazine 

Downstream Products

• 89179-63-5 3-Methoxy-4-amino-pyridazin 
• 1093951-68-8 3-methoxy-4-(tributylstannyl)pyridazine 
• 1263279-79-3 methyl 6-methoxypyrazolo[1,5-b]pyridazine-3-carboxylate 
• 1434271-72-3 (S)-3-(4-bromophenyl)-1-(3-methoxypyridazin-4-yl)-3-o-tolylpropan-1-one 
• 1722-10-7 3-chloro-6-methoxypyridazine 
• 172879-48-0 3-Methoxy-4-(p-tolylsulfonylmethyl)pyridazinium 1-dicyanomethylide 
• 172879-45-7 3-Methoxy-4-(phenylsulfonylmethyl)pyridazinium 1-dicyanomethylide 
• 748141-84-6 [4-(6-methoxy-pyrazolo[1,5-b]pyridazin-3-yl)-pyrimidin-2-yl]-(3-trifluoromethyl-phenyl)-amine 

Relevant academic research and scientific papers

Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5- b]pyridazines for the Treatment of Human African Trypanosomiasis

From a high-throughput screen of 42 44 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis. Previously reported data for analogous compounds against h

IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors

New imidazo[1,2-b]pyridazine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Ring-closing metathesis for the synthesis of heteroaromatics: evaluating routes to pyridines and pyridazines

Ring-closing olefin metathesis (RCM) has been applied to the efficient synthesis of densely and diversely substituted pyridine and pyridazine frameworks. Routes to suitable metathesis precursors have been investigated and the scope of the metathesis step has been probed. The metathesis products function as precursors to the target heteroaromatic structures via elimination of a suitable leaving group, which also facilitates earlier steps by serving as a protecting group at nitrogen. Further functionalisation of the metathesis products is possible both prior to and after aromatisation. The net result is a powerful strategy for the de novo synthesis of highly substituted heteroaromatic scaffolds.

Compounds and Uses Thereof - 848

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, Rsu

PYRAZOLE DERIVATIVES

A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

Anti-tumor compounds

Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and ---- are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder w

N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy

Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.